FDA Accepts Lunsumio VELO Plus Polivy Application After Strong Phase 3 SUNMO Result

The U.S. Food and Drug Administration (FDA) has accepted Roche’s supplemental Biologics License Application (sBLA) seeking approval of subcutaneous Lunsumio VELO (mosunetuzumab) in combination with Polivy (polatuzumab vedotin) for adults with relapsed or refractory large B‑cell lymphoma (LBCL) after at least one prior systemic therapy. The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of February 9, 2027.

Clinical Evidence

The filing is supported by results from the global, randomized Phase 3 SUNMO trial (NCT05171647). At a median follow‑up of 23.2 months, the combination reduced the risk of disease progression or death by 59% compared with rituximab, gemcitabine, and oxaliplatin (R‑GemOx), a standard salvage regimen (HR 0.41; 95% CI, 0.28–0.61; p<0.0001). Median progression‑free survival (PFS) was 11.5 months, more than three times longer than the 3.8 months achieved with R‑GemOx. Updated analyses presented at ASCO 2026 and EHA confirmed sustained benefit, particularly in the second‑line setting.

Safety Profile

Safety findings were consistent with established profiles of both agents. Cytokine release syndrome occurred in approximately one‑quarter of patients, with fewer than 5% experiencing Grade 2–3 events. No new safety signals emerged during extended follow‑up.

Scientific Context

LBCL, predominantly diffuse large B‑cell lymphoma, remains the most common subtype of non‑Hodgkin lymphoma. Up to 40% of patients relapse or develop refractory disease after first‑line therapy, where outcomes are poor and treatment options limited. Lunsumio, a CD20xCD3 bispecific antibody, redirects T cells to eliminate malignant B cells, while Polivy, an antibody‑drug conjugate targeting CD79b, delivers cytotoxic payloads directly to lymphoma cells. Together, the regimen offers a chemotherapy‑free approach suitable for outpatient administration.

Clinical Implications

Levi Garraway, MD, PhD, Roche’s Chief Medical Officer, underscored the urgent need for more effective therapies in relapsed LBCL and highlighted the potential of a chemotherapy‑free, outpatient‑ready regimen. Tara M. Graff, DO, MS, Director of Clinical Research at Mission Cancer and Blood, emphasized the importance of rapid access to effective second‑line therapy and noted the logistical advantages of community‑based treatment. Patient advocacy groups welcomed the development, citing its potential to reduce geographic and access barriers.

Path Forward

If approved, Lunsumio VELO plus Polivy would represent the first subcutaneous bispecific–ADC combination in LBCL, potentially shifting second‑line care toward outpatient delivery. The regimen could expand access beyond academic centers and address treatment gaps in community oncology settings. Roche continues to advance the Lunsumio program across B‑cell malignancies, including ongoing Phase 3 studies in follicular lymphoma.

What This Could Mean for Patients

Relapsed or refractory large B‑cell lymphoma leaves patients with few effective options once initial therapy fails. The FDA’s acceptance of Roche’s application brings this potential new regimen closer to clinical use.

If approved, Lunsumio VELO plus Polivy could deliver a chemotherapy‑free option that tripled median progression‑free survival versus R‑GemOx, while being suitable for outpatient administration. Subcutaneous delivery may simplify treatment and reduce reliance on hospital‑based care, expanding access beyond specialized centers.

For patients ineligible for stem cell transplantation, the regimen could provide a critical new option at a pivotal stage of disease management.

Reference

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma